Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 0.46 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | FER | P16591 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.46 |
| ▸ | NEK4 | P51957 | 1/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.46 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038032 | 0.90 | TRPA1 (0.56) | TRPA1PRKD3MAP4K4CHEK2RET | |
| SCHEMBL6430172 | 0.89 | TRPA1 (0.48) | TRPA1MAPTPPARGSMN1; SMN2KDM4E | |
| SCHEMBL7021132 | 0.89 | TRPA1 (0.57) | TRPA1MAPTSMN1; SMN2MMP13SLC22A8 | |
| SCHEMBL6728256 | 0.88 | TRPA1 (0.56) | TRPA1MAPK1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6462371 | 0.87 | MMP13 (0.52) | TRPA1MAPKAPK2MAPTMMP13SLC22A8 | |
| SCHEMBL6465573 | 0.86 | TRPA1 (0.46) | TRPA1PPARGSMN1; SMN2MMP13SLC22A8 | |
| SCHEMBL6472154 | 0.86 | MEN1 (0.43) | TRPA1DCLK1PRKD3MAP4K4CHEK2 | |
| SCHEMBL7032080 | 0.86 | CA2 (0.46) | TRPA1PPARGSMN1; SMN2KDM4EPOLB | |
| SCHEMBL6245168 | 0.84 | TRPA1 (0.62) | TRPA1MAPK1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL6462194 | 0.84 | TRPA1 (0.43) | TRPA1KDM4EALDH1A1MMP13SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | TRPA1 3888/4885DCLK1 4457/4885PRKD3 3511/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TRPA1 982/4885DCLK1 3287/4885PRKD3 2475/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TRPA1 671/4885DCLK1 3371/4885PRKD3 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.